Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 11 | 2024 | 96 | 6.470 |
Why?
|
| Lung Neoplasms | 17 | 2024 | 552 | 5.130 |
Why?
|
| Thoracic Surgery | 6 | 2024 | 66 | 3.320 |
Why?
|
| Esophageal Neoplasms | 5 | 2024 | 77 | 2.760 |
Why?
|
| Thoracic Surgical Procedures | 5 | 2024 | 32 | 2.480 |
Why?
|
| Surgeons | 4 | 2023 | 155 | 2.210 |
Why?
|
| Thoracic Surgery, Video-Assisted | 6 | 2024 | 51 | 2.020 |
Why?
|
| Pneumonectomy | 6 | 2024 | 82 | 1.670 |
Why?
|
| Esophagectomy | 4 | 2024 | 44 | 1.510 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 139 | 1.330 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 265 | 1.300 |
Why?
|
| Databases, Factual | 8 | 2024 | 837 | 1.170 |
Why?
|
| Thoracic Wall | 2 | 2023 | 16 | 1.030 |
Why?
|
| Pleural Neoplasms | 4 | 2014 | 17 | 0.990 |
Why?
|
| Mesothelioma | 4 | 2014 | 26 | 0.990 |
Why?
|
| Anastomotic Leak | 2 | 2023 | 33 | 0.950 |
Why?
|
| Suture Techniques | 1 | 2024 | 84 | 0.910 |
Why?
|
| Esophageal Achalasia | 1 | 2023 | 29 | 0.830 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2023 | 34 | 0.830 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2022 | 4 | 0.810 |
Why?
|
| Humans | 47 | 2024 | 59380 | 0.800 |
Why?
|
| Herpes Simplex | 1 | 2022 | 46 | 0.770 |
Why?
|
| Clinical Competence | 3 | 2024 | 679 | 0.750 |
Why?
|
| GPI-Linked Proteins | 5 | 2014 | 35 | 0.750 |
Why?
|
| Molecular Imaging | 2 | 2011 | 47 | 0.720 |
Why?
|
| Unnecessary Procedures | 1 | 2020 | 42 | 0.700 |
Why?
|
| Radiation Dosage | 1 | 2020 | 125 | 0.660 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 1464 | 0.630 |
Why?
|
| Retrospective Studies | 15 | 2024 | 5998 | 0.630 |
Why?
|
| Biomedical Research | 1 | 2021 | 250 | 0.610 |
Why?
|
| Societies, Medical | 4 | 2024 | 329 | 0.570 |
Why?
|
| Metastasectomy | 1 | 2016 | 4 | 0.520 |
Why?
|
| Treatment Outcome | 9 | 2024 | 5170 | 0.510 |
Why?
|
| Stomach | 2 | 2012 | 84 | 0.480 |
Why?
|
| Dyspnea | 2 | 2012 | 108 | 0.470 |
Why?
|
| Biomarkers, Tumor | 3 | 2013 | 453 | 0.470 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 2061 | 0.460 |
Why?
|
| Disease Management | 1 | 2016 | 220 | 0.450 |
Why?
|
| Anastomosis, Surgical | 2 | 2024 | 97 | 0.450 |
Why?
|
| Neoplasm Staging | 7 | 2024 | 454 | 0.440 |
Why?
|
| Postoperative Complications | 3 | 2021 | 1132 | 0.440 |
Why?
|
| Tumor Burden | 2 | 2021 | 62 | 0.420 |
Why?
|
| Lymph Nodes | 2 | 2011 | 212 | 0.420 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2024 | 85 | 0.420 |
Why?
|
| Diaphragmatic Eventration | 1 | 2012 | 2 | 0.410 |
Why?
|
| Hernia, Diaphragmatic | 1 | 2012 | 3 | 0.410 |
Why?
|
| Gastric Fistula | 1 | 2012 | 3 | 0.400 |
Why?
|
| Pneumopericardium | 1 | 2012 | 3 | 0.400 |
Why?
|
| Puerperal Disorders | 1 | 2012 | 14 | 0.400 |
Why?
|
| Epithelioid Cells | 1 | 2012 | 4 | 0.400 |
Why?
|
| Pericardium | 1 | 2012 | 35 | 0.390 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 180 | 0.390 |
Why?
|
| Lung | 4 | 2021 | 833 | 0.390 |
Why?
|
| Lymphatic Metastasis | 2 | 2011 | 71 | 0.390 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2012 | 59 | 0.390 |
Why?
|
| Thoracotomy | 3 | 2021 | 45 | 0.370 |
Why?
|
| Cesarean Section | 1 | 2012 | 96 | 0.370 |
Why?
|
| Surgical Flaps | 1 | 2012 | 102 | 0.360 |
Why?
|
| Models, Animal | 1 | 2011 | 221 | 0.360 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 196 | 0.360 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 46 | 0.360 |
Why?
|
| Oximetry | 1 | 2010 | 47 | 0.350 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2010 | 87 | 0.340 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 323 | 0.340 |
Why?
|
| Pneumothorax | 2 | 2024 | 43 | 0.330 |
Why?
|
| Esophagus | 2 | 2023 | 53 | 0.310 |
Why?
|
| Research Support as Topic | 1 | 2009 | 44 | 0.310 |
Why?
|
| Female | 19 | 2024 | 30862 | 0.310 |
Why?
|
| Health Care Reform | 1 | 2009 | 88 | 0.310 |
Why?
|
| Bronchogenic Cyst | 1 | 2008 | 2 | 0.310 |
Why?
|
| Science | 1 | 2009 | 34 | 0.310 |
Why?
|
| Mediastinal Neoplasms | 1 | 2008 | 13 | 0.310 |
Why?
|
| Pancreatic Neoplasms | 2 | 2010 | 317 | 0.300 |
Why?
|
| Carcinoid Tumor | 1 | 2008 | 14 | 0.300 |
Why?
|
| Insurance, Health | 1 | 2009 | 141 | 0.300 |
Why?
|
| Epidermal Cyst | 1 | 2008 | 10 | 0.300 |
Why?
|
| Neoplasms, Second Primary | 1 | 2008 | 41 | 0.300 |
Why?
|
| Splenic Diseases | 1 | 2008 | 14 | 0.300 |
Why?
|
| Pancreatic Diseases | 1 | 2008 | 39 | 0.300 |
Why?
|
| Choristoma | 1 | 2008 | 24 | 0.300 |
Why?
|
| Middle Aged | 14 | 2024 | 16237 | 0.290 |
Why?
|
| Aged | 13 | 2024 | 13329 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 192 | 0.280 |
Why?
|
| Quality Improvement | 2 | 2022 | 424 | 0.270 |
Why?
|
| Spleen | 1 | 2008 | 485 | 0.270 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2006 | 12 | 0.260 |
Why?
|
| Prognosis | 6 | 2022 | 1571 | 0.260 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 645 | 0.260 |
Why?
|
| Computer-Assisted Instruction | 1 | 2006 | 81 | 0.250 |
Why?
|
| Urinary Bladder | 1 | 2024 | 33 | 0.240 |
Why?
|
| Feedback | 1 | 2024 | 87 | 0.240 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2006 | 146 | 0.230 |
Why?
|
| Male | 14 | 2024 | 27516 | 0.230 |
Why?
|
| Hospitals, Low-Volume | 1 | 2024 | 21 | 0.230 |
Why?
|
| Random Allocation | 1 | 2024 | 198 | 0.230 |
Why?
|
| Hospitals, High-Volume | 1 | 2024 | 36 | 0.230 |
Why?
|
| Aorta | 1 | 2024 | 106 | 0.230 |
Why?
|
| Animals | 9 | 2024 | 19635 | 0.220 |
Why?
|
| Swine | 1 | 2024 | 344 | 0.220 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 900 | 0.220 |
Why?
|
| Curriculum | 2 | 2024 | 550 | 0.220 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2023 | 20 | 0.220 |
Why?
|
| General Surgery | 1 | 2006 | 187 | 0.210 |
Why?
|
| Time Factors | 3 | 2024 | 3571 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 4 | 2022 | 243 | 0.210 |
Why?
|
| Benchmarking | 2 | 2023 | 135 | 0.210 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 1129 | 0.210 |
Why?
|
| Endoscopy | 1 | 2023 | 97 | 0.200 |
Why?
|
| Bronchoscopes | 1 | 2022 | 8 | 0.200 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2023 | 117 | 0.200 |
Why?
|
| Simplexvirus | 1 | 2022 | 24 | 0.200 |
Why?
|
| Virtual Reality | 1 | 2022 | 12 | 0.200 |
Why?
|
| Bronchoscopy | 1 | 2022 | 64 | 0.200 |
Why?
|
| Adult | 11 | 2024 | 15753 | 0.190 |
Why?
|
| Learning | 1 | 2023 | 171 | 0.190 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 3 | 0.190 |
Why?
|
| Carbon Monoxide | 1 | 2021 | 59 | 0.190 |
Why?
|
| Robotics | 1 | 2022 | 48 | 0.190 |
Why?
|
| Simulation Training | 1 | 2022 | 58 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 233 | 0.180 |
Why?
|
| Data Warehousing | 1 | 2020 | 8 | 0.180 |
Why?
|
| Medicare | 1 | 2024 | 600 | 0.170 |
Why?
|
| United States | 5 | 2024 | 7512 | 0.170 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 330 | 0.170 |
Why?
|
| Diagnostic Errors | 1 | 2020 | 98 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2022 | 301 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 1027 | 0.160 |
Why?
|
| Program Evaluation | 1 | 2020 | 484 | 0.150 |
Why?
|
| Colorectal Neoplasms | 2 | 2012 | 254 | 0.150 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 1548 | 0.140 |
Why?
|
| Diagnostic Imaging | 2 | 2011 | 242 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 404 | 0.140 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 2326 | 0.140 |
Why?
|
| Recurrence | 2 | 2024 | 576 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 2 | 2012 | 104 | 0.120 |
Why?
|
| Mice | 4 | 2013 | 10270 | 0.120 |
Why?
|
| Gallbladder Diseases | 1 | 2015 | 26 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 35 | 0.120 |
Why?
|
| Patient Selection | 2 | 2015 | 446 | 0.120 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2015 | 46 | 0.120 |
Why?
|
| Drainage | 2 | 2012 | 145 | 0.120 |
Why?
|
| Cell Proliferation | 3 | 2014 | 942 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2014 | 87 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 5091 | 0.110 |
Why?
|
| Cell Movement | 2 | 2013 | 422 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 279 | 0.100 |
Why?
|
| Rupture, Spontaneous | 1 | 2012 | 22 | 0.100 |
Why?
|
| Esophageal Atresia | 1 | 2012 | 10 | 0.100 |
Why?
|
| Sternotomy | 1 | 2012 | 12 | 0.100 |
Why?
|
| Laparotomy | 1 | 2012 | 46 | 0.100 |
Why?
|
| Methods | 1 | 2011 | 38 | 0.100 |
Why?
|
| Barrett Esophagus | 1 | 2012 | 34 | 0.100 |
Why?
|
| Osteopontin | 1 | 2011 | 22 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2012 | 209 | 0.090 |
Why?
|
| Oncolytic Viruses | 1 | 2011 | 7 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 192 | 0.090 |
Why?
|
| Chest Pain | 1 | 2012 | 84 | 0.090 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2011 | 6 | 0.090 |
Why?
|
| Pleurodesis | 1 | 2011 | 4 | 0.090 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 37 | 0.090 |
Why?
|
| Chest Tubes | 1 | 2011 | 14 | 0.090 |
Why?
|
| Reoperation | 1 | 2012 | 254 | 0.090 |
Why?
|
| Sus scrofa | 1 | 2010 | 26 | 0.090 |
Why?
|
| Young Adult | 3 | 2024 | 4316 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 63 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 43 | 0.090 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 291 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 608 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 525 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2012 | 593 | 0.090 |
Why?
|
| Palliative Care | 2 | 2011 | 202 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 658 | 0.090 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2010 | 1 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2012 | 638 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2012 | 879 | 0.090 |
Why?
|
| Intestines | 1 | 2010 | 156 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 276 | 0.080 |
Why?
|
| Politics | 1 | 2009 | 31 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 569 | 0.080 |
Why?
|
| India | 1 | 2009 | 157 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 699 | 0.080 |
Why?
|
| Thigh | 1 | 2008 | 25 | 0.080 |
Why?
|
| Kidney | 1 | 2010 | 393 | 0.080 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 172 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2014 | 734 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 63 | 0.070 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2008 | 61 | 0.070 |
Why?
|
| Survival Rate | 2 | 2024 | 790 | 0.070 |
Why?
|
| Rats | 1 | 2010 | 1912 | 0.070 |
Why?
|
| Length of Stay | 2 | 2024 | 769 | 0.070 |
Why?
|
| Apoptosis | 1 | 2012 | 1038 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1469 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2012 | 1912 | 0.060 |
Why?
|
| Pleura | 1 | 2024 | 11 | 0.060 |
Why?
|
| Emergency Service, Hospital | 1 | 2012 | 1022 | 0.060 |
Why?
|
| Consensus | 1 | 2024 | 193 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2014 | 506 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2014 | 511 | 0.050 |
Why?
|
| Suction | 1 | 2022 | 30 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 310 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 386 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 74 | 0.050 |
Why?
|
| Neoplasms | 1 | 2011 | 1243 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 299 | 0.040 |
Why?
|
| Water | 1 | 2022 | 295 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 1373 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 208 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2022 | 456 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2024 | 727 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2015 | 3095 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2015 | 6 | 0.030 |
Why?
|
| Chimerism | 1 | 2014 | 10 | 0.030 |
Why?
|
| Operative Time | 1 | 2015 | 63 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2014 | 142 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 159 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 233 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 233 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2014 | 574 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2012 | 18 | 0.030 |
Why?
|
| Mucins | 1 | 2012 | 23 | 0.020 |
Why?
|
| Camptothecin | 1 | 2012 | 23 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 739 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 77 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2012 | 132 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2012 | 59 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 151 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 138 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 176 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 885 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 807 | 0.020 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2010 | 56 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 925 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2014 | 1293 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1053 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 919 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 553 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1043 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2009 | 2441 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 5010 | 0.010 |
Why?
|